Experience with generic drugs in epilepsy patients: An electronic survey of members of the German, Austrian and Swiss branches of the ILAE [1]

Epilepsia

Volumn 48, Issue 3, 2007, Pages 609-611

  Krämer, Günter ^a   Steinhoff, Bernhard J ^b   Feucht, Martha ^c   Pfäfflin, Margerete ^d   May, Theodor W ^d  

^a SWISS EPILEPSY CENTER   (Switzerland)

^b Epilepsy Centre Kork   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Society for Epilepsy Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN;

AUSTRIA; BIOEQUIVALENCE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE EXACERBATION; DOCTOR PATIENT RELATION; DRUG APPROVAL; DRUG EFFECT; DRUG SUBSTITUTION; DRUG UTILIZATION; ELECTRONIC MEDICAL RECORD; EMERGENCY PHYSICIAN; EMERGENCY WARD; EPILEPSY; GERMANY; HEALTH SURVEY; HOSPITALIZATION; HUMAN; LETTER; LICENSING; MEDICAL PRACTICE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT DISEASE; SEIZURE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SWITZERLAND; TELECONSULTATION; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANTICONVULSANTS; AUSTRIA; DRUGS, GENERIC; EPILEPSY; GERMANY; HEALTH CARE SURVEYS; INTERNATIONAL AGENCIES; PHYSICIAN'S PRACTICE PATTERNS; SWITZERLAND; THERAPEUTIC EQUIVALENCY;

EID: 33847627126     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2007.01084_1.x     Document Type: Letter

References (10)

1. Blume H, Bauer KG, Dingermann T, Mutschler E, Zündorf I. (2002) Gute Substitutionspraxis - GSP. Deutsche Apotheker-Zeitung 142:1205-1214.
2. Burkhardt RT, Leppik IE, Blesi K, et al. (2004) Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 63:1494-1496.
3. Crawford P, Feely M, Guberman A, Krämer G. (2006) Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 15:165-176.
4. Gilman JT, Alvarez LA, Duchowny M. (1993) Carbamazepine toxicity resulting from generic substitution. Neurology 43:2696-2697.
5. Krämer G, Dennig D, Schmidt D, et al (ad-hoc-Kommission der Deutschen Gesellschaft für Epileptologie). (2005) Generika in der Epilepsietherapie: was ist zu beachten? Akt Neurol 32:275-278.
6. Krämer G, Schneble H, Wolf P (ad-hoc-Kommission der Deutschen Sektion der Internationalen Liga gegen Epilepsie). (2002) Risiken der neuen aut-idem-regelung für die Behandlung mit Antiepileptika. Akt Neurol 29:115-122.
7. Laroche ML, Traore H, Merle L, et al. (2005) Quality of phenobarbital solid-dosage forms in the urban community of Nouakchott (Mauritania). Epilepsia 46:1293-1296.
8. Oles KS, Penry JK, Smith LD, et al. (1992) Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology 42:1147-1153.
9. Roth-Isigkeit A, Harder S. (2005) Die Entlassungsmedikation im arztbrief-eine explorative befragung von hausärzten/-innen. Med Klin (München) 100:87-93.
10. Wilner AN. (2004) Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy and Behavior 5:995-998.